Set to start in 2025, Relay Therapeutics is moving toward a pivotal study of experimental treatment RLY-2608 in heavily ...

RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.

The candidate is being developed as a monotherapy, in combination with AstraZeneca’s Faslodex and also in combination with ...

Kisqali (ribociclib) given alongside endocrine therapy ... for approval of Kisqali in the new indication later this year. AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder ...

Patients would have to wait to access the treatment, however, as the FDA would not approve AstraZeneca’s Nolvadex ... The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.